Life Science Tools Market Size, Share & Trends Analysis Report By Technology (Cell Biology, Genomics), By Product (Flow Cytometry, Mass Spectrometry), By End-use, By Region, And Segment Forecasts, 2021 - 2028

Report Overview

The global life science tools market size was computed at USD 92.2 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 11.9% from 2021 to 2028. The anticipated growth in revenue is attributed to rapid technological advancements adopted by the life science tools companies in mass spectrometry, sequencing technologies, chromatography methods, NMR, and other products. An exponential rise in the COVID-19 cases globally boosts the demand for life science tools for rapid diagnosis.

As the world is engaged in curbing the spread of COVID-19, automation and robotic technologies play an important role in accelerating manual and redundant tasks in pharmaceutical companies and laboratories. To overcome the COVID-19 pandemic, drug developers are continuously working on the development of vaccines and other treatment options. The robotic companies are highly active in this space and are offering automated solutions to drug developers for rapid labor-extensive steps.

In March 2020, the Hamilton Company introduced two automated assay-ready workstations, the MagEx STARlet and Prep STARlet, to assist healthcare professionals and researchers engaged in coronavirus research. These two automated workstations are based on the Microlab STARlet liquid handling workstation of Hamilton, which, in turn, facilitates rapid, high-throughput research and diagnostic-based testing of SARS-CoV-2. 

Several initiatives are undertaken by biopharma companies to gain a competitive advantage in the COVID-19 cell therapy space. The players are adopting various market entry strategies, e.g., biopharma facility expansion, collaborations with other key stakeholders, and the development of contract manufacturing organizations.

The pandemic has also established public/private partnerships for vaccine development. For instance, Operation Warp Speed (OWS) brings together various federal government departments in the U.S., including Health and Human Services. This collaboration has funded Phase 3 trials for BioNTech's BNT162 from Pfizer, AZD1222 from AstraZeneca and Oxford University, and mRNA-1273 from Moderna. Other major initiatives include ACTIV, CoVPN, and COVAX.

Therefore, an increase in R&D for the development of vaccines for COVID-19 has increased the demand for technologies used for bio-processing, including cell culture. Moreover, Trizol and detergents are used for RNA extraction and virus inactivation for downstream biological assays. Owing to these factors, key companies have generated substantial revenue for their bioprocessing offerings.

Technology Insights

The cell biology technology segment dominated the market for life science tools and accounted for the largest revenue share of 33.9%in 2020. The segment is closely followed by genomics technology. Traditional genome editing technologies have a limited capacity of maintaining pace with the fast-progressing genome modification era, owing to the fact that these technologies are time-consuming, inefficient, and labor-intensive.

The advent of CRISPR/Cas9 nuclease and ZFN facilitates easy and precise genome editing. In recent times, the genomics industry has witnessed a substantial number of advancements and expansion of the application of gene editing tools for the treatment of genetic diseases. This has significantly impacted the growth of the market for life science tools.

The proteomics segment is expected to expand at a significant CAGR as proteome analysis can provide a complete depiction of functional and structural information of the cell and their response mechanisms against drugs and other foreign factors. Mass spectrometry is one of the key technologies employed during proteomic workflows. Therefore, technical advances in the field of mass spectrometry drive the capabilities for proteomic discovery.

Product Insights

The cell culture systems and 3D cell culture segment dominated the market for life science tools and accounted for the largest revenue share of 17.9% in 2020. However, the nucleic acid microarray and cloning and genome engineering segments are expected to register lucrative growth rates. The COVID-19 pandemic has significantly propelled the growth of the bioprocessing industry and thereby driving the cell culture systems and 3D cell culture systems. Companies have accelerated their efforts to develop the SARS-CoV-2 vaccine.

The PCR and qPCR segment witnessed substantial growth from 2019 to 2020 owing to high utilization in COVID-19 diagnosis. COVID-19 detection tests are based on RT-PCR technology for quantification of RNA in the samples of coronavirus-affected patients. Large-scale adoption of PCR across government bodies, such as the CDC, commercial laboratories, hospitals, and public health laboratories, has made significant contributions to the revenue generated by this product segment in the market for life science tools.

Moreover, a number of approvals being granted for use of RT-PCR-based molecular diagnostic tests for early detection of COVID-19 drive the segment. The nucleic acid microarray segment is expected to expand at the fastest CAGR. Leading players have developed several advanced instruments for microarray analysis. This has increased the adoption of DNA microarrays among researchers and laboratories.

End-use Insights

The health care segment dominated the market for life science tools and accounted for the largest revenue share of 33.7% in 2020. This segment comprises hospitals, clinics, diagnostic laboratories, community centers, and physician offices. Increasing adoption of genomic and proteomic workflows in hospitals to diagnose and treat several clinical abnormalities is expected to drive the market for life science tools.

In addition, efforts taken by hospitals and clinics to expand their genomics research gateway are also expected to enhance the growth of life science tools. Several hospitals and clinics are currently offering sequencing services to patients and are determining the use of this technology in the daily practice of medicine.

Stanford Medicine is one such hospital that offers sequencing services to individuals who have a rare or undiagnosed condition that is believed to be genetic. Partners HealthCare in the U.S. is one of the first hospital systems to provide genomic sequencing, analysis, and interpretation services to the public. In addition, the growing adoption of NGS services and tissue diagnostic services in hospitals is expected to drive the market for life science tools.

In addition, owing to the rising demand for the diagnostic tests for Covid-19, a pandemic disease declared by the WHO, U.S. FDA has given an emergency approval to a diagnostic, under which, test manufacturer Roche, received an Emergency Use Authorization (EUA). Such initiatives are expected to drive the adoption of life science tools in the diagnostics sector.

Regional Insights

North America dominated the market for life science tools and accounted for the largest revenue share of 46.1% in 2020 owing to the factors such as the local presence of leading market players such as Thermo Fisher Scientific, a reputable informatics network, and a well-regulated framework for usage and approval of genomic tests in the region. In addition, a rise in the number of genomic procedures for academic and clinical use in the U.S. is expected to drive the market for life science tools in North America throughout the forecast period.

In Asia Pacific, the market for life science tools is poised to witness the fastest growth throughout the forecast period owing to the growing penetration of leading players in emerging Asian countries and investments for the design of advanced diagnostic methods. Asia Pacific is a lucrative destination for outsourcing pharmaceutical R&D as the region provides skilled professionals at a much lower cost than developed countries in North America and Europe. Therefore, global CROs have expanded their presence in the Asia Pacific owing to lucrative opportunities in several Asian countries.

Key Companies & Market Share Insights

Thermo Fisher Scientific is one of the largest suppliers of a wide range of innovative solutions for the life science community across the globe. The company’s products are used by researchers and healthcare professionals globally. The company’s portfolio includes nucleic acid purification solutions, flow cytometry instruments, sequencing solutions, thermal cyclers, and other laboratory supplies.

In addition, Affymetrix Inc, a subsidiary of Thermo Fisher Scientific is the leading player in the nucleic acid microarrays market. The chromatography market is dominated by AgilentTechnologies with a strong foothold in the High-performance liquid chromatography and gas chromatography markets. Some of the prominent players in the life science tools market include:

• Agilent Technologies

• Becton, Dickinson and Company

• F. Hoffmann-La Roche AG

• Bio-Rad Laboratories, Inc.

• Danaher Corporation

• Illumina, Inc.

• Thermo Fisher Scientific, Inc

• QIAGEN

• Merck KGaA

• Shimadzu Corporation

• Hitachi, Ltd.

• Bruker

• Oxford Instruments plc

• Zeiss International

Life Science Tools Market Report Scope

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2028. For the purpose of this study, Grand View Research has segmented the global life science tools market report on the basis of technology, product, end-use, and region:

• Technology Outlook (Revenue, USD Million, 2017 - 2028)

  • Genomic Technology

  • Proteomics Technology

  • Cell Biology Technology

  • Other Analytical & Sample Preparation Technology

  • Lab Supplies & Technologies

• Product Outlook (Revenue, USD Million, 2017 - 2028)

  • Cell Culture Systems & 3D Cell Culture

    • Instrument

    • Consumables

    • Cell & Tissue Culture Services

  • Liquid Chromatography

    • Instrument

    • Consumables

    • Services

  • Mass Spectrometry

    • Instrument

    • Consumables

    • Services

  • Flow Cytometry

    • Instrument

    • Consumables

    • Services

  • Cloning & Genome Engineering

    • Kits, Reagents, and Consumables

    • Services

  • Microscopy & Electron Microscopy

    • Instrument

    • Consumables

    • Services

  • Next Generation Sequencing

    • Instrument

    • Consumables

    • Services

  • PCR & qPCR

    • Instrument

    • Consumables

    • Services

  • Nucleic Acid Preparation

    • Instrument

    • Consumables

    • Services

  • Nucleic Acid Microarray

    • Instrument

    • Consumables

    • Services

  • Sanger Sequencing

    • Instrument

    • Consumables

    • Services

  • Transfection Devices & Gene Delivery Technologies

    • Equipment

    • Reagents

  • NMR

    • Instrument

    • Consumables

    • Services

  • Other Separation Technologies

    • Instrument

    • Consumables

    • Services

  • Other Products & Services

    • Antibody Assays

    • General Supplies

    • Others

      • Instrument

      • Consumables

      • Services

• End-use Outlook (Revenue, USD Million, 2017 - 2028)

  • Government & Academic

  • Biopharmaceutical Company

  • Health Care

  • Industry

  • Others

• Regional Outlook (Revenue, USD Million, 2017 - 2028)

  • North America

    • U.S.

    • Canada

  • Europe

    • Germany

    • U.K.

  • Asia Pacific

    • Japan

    • China

    • India

  • Latin America

    • Brazil

    • Mexico

  • MEA

    • South Africa

    • Saudi Arabia